Drug intelligence / Profile preview

VYR-108

Development stage: Preclinical
Lead developer: Vyripharm Biopharmaceuticals
Modality: Hydrogel Systems → Drug Delivery Systems

Overview

VYR-108 is an investigational hydrogel-based drug delivery system being developed by Vyripharm International for oncological applications. The platform is designed to encapsulate therapeutic agents to facilitate controlled, localized release within the tumor microenvironment, aiming to enhance the therapeutic index of cancer treatments by maximizing local concentration while minimizing systemic exposure. Currently in the IND-enabling phase, VYR-108 represents Vyripharm's efforts to integrate advanced material science with targeted cancer therapy.

Beyond the preview

Go deeper on VYR-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VYR-108.

Explore the full profile